01.13.26 -- 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For

By addressing considerations for a comprehensive reference standard strategy, manufacturers can ensure the integrity of biopharmaceuticals, ultimately paving the way for better patient outcomes.

Discover current and emerging technologies to optimize mRNA manufacturing, especially when considering commercial production and the validation of processes in a cGMP environment.

For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.

The complex biology of rare diseases creates unique hurdles, making it difficult to design and implement a drug development program. Examine the unique considerations for drug product manufacturing.

Understanding the obstacles you may face during bioconjugate development, as well as the tools available to help overcome them, can help streamline your product’s path to market.

Navigating drug development requires more than science; it demands collaboration. Learn three essential factors that strengthen partnerships, reduce risk, and accelerate progress from lab to bedside.

Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.